Mark Pimentel, M.D., is Professor of Medicine, Geffen School of Medicine and Associate Professor at Cedars‐Sinai Medical Center in Los Angeles, California.
Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine.
His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co‐investigator for numerous basic‐science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease.
His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others.
Dr. Pimentel has been invited to present his work at meetings, grand rounds and advisory boards in the United States and Internationally. He is diplomate of the American Board of Internal Medicine (Gastroenterology) and a fellow of the Royal College of Physicians and Surgeons of Canada.
Dr. Pimentel is also a member of several medical associations including the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.
A few of Dr. Pimentel’s most significant accomplishments include:
- The discovery of rifaximin as a treatment for irritable bowel syndrome (IBS)
- He developed the first blood test for IBS on the basis of IBS being derived from acute gastroenteritis
- Described the association between IBS and bacterial overgrowth which forms the basis for microbiome therapies in this condition
- Uncovered the methanogen ( smithii) as an agent for causing constipation in humans.
- Discovered the use of lovastatin as a microbiome treatment for constipation on the basis of inhibiting methane production by methanogens
Learning Points:
- What is SIBO?
- What are signs and symptoms of SIBO?
- How is SIBO treated?
Social Media
https://twitter.com/MarkPimentelMD
https://www.cedars-sinai.edu/Research/Research-Labs/Pimentel-Lab/
Listen live or catch the podcast on iTunes and SoundCloud!
Every Tuesday from 11am -12pm I host The Health Hub, an interactive, forward thinking talk show on Radio Maria Canada. Call, tweet or email your questions as together we explore health issues that are relevant to you from new and innovative points of view.
TheHealthHub is now on iTunes!
Subscribe and don’t miss a single episode!
Follow us on Social Media
We are @thehealthhubrmc on Instagram, Twitter and Facebook
How To Listen Live
Visit our website and learn how to listen live to our show each week. http://www.radiomaria.ca/how-to-listen
Let us know!
If you have a health topic that you would like us to discuss or are a health care specialist who wants to be a guest on our show let us know!
Here is our email. We would love to hear from you! thh@radiomaria.ca